ARS Pharmaceuticals Investor Relations Material
Latest events
Q1 2025
ARS Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ARS Pharmaceuticals Inc
Access all reports
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on developing treatments for patients and caregivers affected by severe allergic reactions, including anaphylaxis. The company's flagship product in development is Neffy, a needle-free, low-dose intranasal epinephrine nasal spray designed to offer a safe, effective, and user-friendly alternative to traditional injectable epinephrine devices. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Latest articles
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
Ticker symbol
SPRY
Country
🇺🇸 United States